Literature DB >> 10101811

Antioxidant and prooxidant actions of estrogens: potential physiological and clinical implications.

L Nathan1, G Chaudhuri.   

Abstract

Oxidative stress and free radical-mediated cell death have been linked to diseases such as atherosclerosis, Alzheimer's disease, and cancer. Estrogens may promote, or offer protection against these conditions, by acting both as an antioxidant and prooxidant. Estrogens are converted to catecholestrogens via an oxidation step. Catecholestrogens are precursors of quinones that undergo a reversible oxidation-reduction reaction yielding semiquinones and reactive oxygen species. These semiquinones and reactive oxygen species may act as prooxidants and result in DNA and protein damage that may play a role in initiating tumor growth. Estrogen may also stimulate the peroxidase reaction, thereby promoting prooxidant reactions catalyzed by estrogen. Such reactions may be involved in enhancing the oxidizability of low-density lipoproteins (LDL). This mechanism of oxidation of LDL in plasma may actually lead to increased clearance of LDL by the liver and thereby contribute to estrogens' antiatherogenic action. On the other hand, participation of catecholestrogens in iron redox cycling may contribute to the antioxidant action of estrogens. This action might be important in sites such as the subendothelial space where estrogens are thought to inhibit LDL oxidation. Estrogens may also exert antioxidant effects by acting on genes with response elements for antioxidants. This may in turn inhibit expression of certain proteins involved in disease processes such as atherogenesis. Thus, by acting as an antioxidant and prooxidant, estrogen may produce both beneficial and adverse effects important in the prevention and pathogenesis of disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10101811     DOI: 10.1055/s-2007-1016289

Source DB:  PubMed          Journal:  Semin Reprod Endocrinol        ISSN: 0734-8630


  14 in total

1.  Update on Alzheimer's disease: recent findings and treatments.

Authors:  R O'Hara; M S Mumenthaler; J A Yesavage
Journal:  West J Med       Date:  2000-02

2.  Decreased oxidant profile and increased antioxidant capacity in naturally postmenopausal women.

Authors:  V J Victorino; C Panis; F C Campos; R C Cayres; A N Colado-Simão; S R Oliveira; A C S A Herrera; A L Cecchini; R Cecchini
Journal:  Age (Dordr)       Date:  2012-05-28

3.  Pharmacotherapy in the treatment of Alzheimer's disease: an update.

Authors:  Brian E Leonard
Journal:  World Psychiatry       Date:  2004-06       Impact factor: 49.548

Review 4.  Could oxidative stress influence the in-vitro maturation of oocytes?

Authors:  Catherine M H Combelles; Sajal Gupta; Ashok Agarwal
Journal:  Reprod Biomed Online       Date:  2009-06       Impact factor: 3.828

Review 5.  Roles of reactive oxygen species and antioxidants in ovarian toxicity.

Authors:  Patrick J Devine; Sally D Perreault; Ulrike Luderer
Journal:  Biol Reprod       Date:  2012-02-09       Impact factor: 4.285

6.  Plasma phosphatidylcholine concentrations of polyunsaturated fatty acids are differentially associated with hip bone mineral density and hip fracture in older adults: the Framingham Osteoporosis Study.

Authors:  Emily K Farina; Douglas P Kiel; Ronenn Roubenoff; Ernst J Schaefer; L Adrienne Cupples; Katherine L Tucker
Journal:  J Bone Miner Res       Date:  2012-05       Impact factor: 6.741

7.  Effect of growth hormone and estrogen administration on hepatocyte alterations in old ovariectomized female wistar rats.

Authors:  Carmen Castillo; Veronica Salazar; Carmen Ariznavarreta; Elena Vara; Jesus A F Tresguerres
Journal:  Endocrine       Date:  2005-02       Impact factor: 3.633

8.  Associations differ by sex for catechol-O-methyltransferase genotypes and bladder cancer risk in South Egypt.

Authors:  Beverly J Wolpert; Sania Amr; Doa'a A Saleh; Sameera Ezzat; Iman Gouda; Iman Loay; Tamer Hifnawy; Mohamed Abdel-Hamid; Nabiel N Mikhail; Min Zhan; Yun-Ling Zheng; Katherine Squibb; Mohamed A Abdel-Aziz; Mohamed S Zaghloul; Hussein Khaled; Christopher A Loffredo
Journal:  Urol Oncol       Date:  2011-03-11       Impact factor: 3.498

9.  Tamoxifen decreases ovarian follicular loss from experimental toxicant DMBA and chemotherapy agents cyclophosphamide and doxorubicin in the rat.

Authors:  Alison Y Ting; Brian K Petroff
Journal:  J Assist Reprod Genet       Date:  2010-08-14       Impact factor: 3.412

10.  Oestrogen metabolites in relation to isoprostanes as a measure of oxidative stress.

Authors:  MaryFran Sowers; Daniel McConnell; Mary L Jannausch; John F Randolph; Robert Brook; Ellen B Gold; Sybil Crawford; Bill Lasley
Journal:  Clin Endocrinol (Oxf)       Date:  2007-11-02       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.